Navigation Links
Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Date:9/4/2007

CORONA, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received its first U.S. Food and Drug Administration (FDA) product approval at its Goa, India facility. During the next several months the company plans to seek FDA approval to manufacture additional solid dosage products at the facility. By early 2008, the Goa facility is expected to be producing over 1 billion tablets and capsules annually for the U.S. market.

"This approval represents a key milestone for Watson, demonstrating our rapid progress toward building an offshore infrastructure," said Allen Chao, Ph.D., Watson's Executive Chairman. "In the coming months we anticipate making additional FDA submissions to transfer certain products to this facility to achieve efficiencies in scale and cost. This will enhance our ability to provide quality, low cost generic pharmaceutical products to the U.S. marketplace."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, difficulties or delays in transferring product manufacturing to the Goa facility; difficulties or delays in obtaining U.S. Food and Drug Administration or other regulatory approvals to manufacture products at the Goa, India site for the U.S. market; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Pravastatin Launched by Watson Pharmaceuticals
3. Watson Amazed by Radcliffes Steamy Shots
4. Infant receives first bloodless liver transplant
5. Fifth US Patient Receives Artificial Heart
6. Northfield Labs Receives FDA Comments
7. British MPs Say Prostate Cancer Receives Low Priority in the NHS
8. Abbott Receives CE Mark Certification
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: